\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\ \\ not\\ available\ \(0\)\
\-\ laboratory\\:\\-\\-\\ 3\\ oligoclonal\\ bands\\ seen\\ in\\ csf\\;\\ no\\ oligoclonal\\ bands\\ present\\ in\\ serum\\-\\-\\ serum\\ cardiolipin\\ igg\\,\\ igm\\,\\ iga\\ negative\\-\\-\\ ds\\ dna\\ ab\\ positive\\ \\(28\\ iu\\/ml\\)\\-\\-\\ ena\\ negative\\-\\-\\ lyme\\ ab\\ total\\ borderline\\;\\ b\\.\\ burgdorferi\\ igg\\,\\ igm\\ negative\ \(0\)\
\-\ there\\ are\\ multifocal\\ areas\\ of\\ predominately\\ white\\ matter\\ abnormal\\ signal\\ intensity\\ \\ several\\ lesions\\ are\\ in\\ the\\ corpus\\ callosum\\,\\ the\\ largest\\ seen\\ in\\ the\\ body\\ of\\ the\\ corpus\\ callosum\\;\\ with\\ periventricular\\ and\\ periatrial\\ predominance\\.\\ \\ \ \(0\)\
\-\ several\\ lesions\\ are\\ oriented\\ perpendicular\\ to\\ the\\ corpus\\ callosum\\ \\(dawson\\â\\€\\™s\\ fingers\\)\\.\\ \ \(0\)\
\-\ similar\\ hyperintense\\ lesions\\ are\\ also\\ seen\\ in\\ the\\ brain\\ stem\\ and\\ spinal\\ cord\\,\\ best\\ seen\\ on\\ the\\ sagittal\\ images\\.\ \(0\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ 1\\.\\ \\ cerebral\\ autosomal\\ dominant\\ arteriopathy\\ with\\ subcortical\\ infarct\\ \\(cadasil\\)\ \(0\)\
\-\ 2\\.\\ \\ lyme\\ disease\ \(0\)\
\-\ 3\\.\\ \\ central\\ nervous\\ system\\ vasculitis\ \(0\)\
\-\ 4\\.\\ \\ multiple\\ sclerosis\ \(0\)\
\-\ 5\\.\\ adem\\ \\(acute\\ disseminated\\ encephalomyelitis\ \(0\)\
\-\ 25\\ y\\/o\\ woman\\ has\\ left\\ ue\\ weakness\\ and\\ chorea\\;\\ with\\ sensory\\ loss\\ to\\ her\\ left\\ arm\\.\\ \\ rapidly\\ worsening\\ of\\ spasm\\ in\\ the\\ wrist\\ and\\ hand\\.\ \(0\)\
\-\ multiple\\ sclerosis\\ \\(ms\\)\\ is\\ a\\ multifocal\\ disease\\ with\\ a\\ complex\\ pathogenesis\\ that\\ includes\\ inflammation\\ and\\ potentially\\ disabling\\ focal\\ lesions\\ that\\ disseminate\\ throughout\\ the\\ central\\ nervous\\ system\\.\\ \\ it\\ is\\ the\\ most\\ common\\ primary\\ myelin\\ disorder\\,\\ with\\ an\\ estimated\\ patient\\ prevalence\\ of\\ 250\\,000\\ to\\ 350\\,000\\ in\\ the\\ united\\ states\\.\\ \\ eighty\\ percent\\ of\\ patients\\ have\\ relapsing\\-remitting\\ ms\\,\\ and\\ the\\ minority\\ of\\ patients\\ has\\ primary\\ progressive\\ ms\\.\\ \\ this\\ subtype\\ of\\ ms\\ usually\\ begins\\ in\\ the\\ second\\ or\\ third\\ decade\\ of\\ life\\ and\\ has\\ a\\ female\\ predominance\\ of\\ approximately\\ 2\\:1\\.\\ \\ the\\ prevalence\\ is\\ highest\\ in\\ northern\\ europe\\,\\ however\\,\\ the\\ occurrence\\ of\\ rapid\\ shifts\\ in\\ the\\ incidence\\ of\\ ms\\ have\\ been\\ reported\\ in\\ recent\\ studies\\.\ \(0\)\
\-\ the\\ pathogenesis\\ of\\ ms\\ remains\\ unclear\\ today\\.\\ \\ however\\,\\ a\\ multifactorial\\ pathogenetic\\ mechanism\\ has\\ been\\ postulated\\ given\\ the\\ heterogeneity\\ of\\ clinical\\,\\ genetic\\,\\ and\\ radiological\\ studies\\ of\\ ms\\.\\ \\ the\\ pathological\\ hallmark\\ of\\ chronic\\ ms\\ is\\ the\\ demyelinated\\ plaque\\,\\ which\\ consisted\\ of\\ a\\ well\\-demarcated\\ hypocellular\\ area\\ characterized\\ by\\ the\\ loss\\ of\\ myelin\\,\\ relative\\ preservation\\ of\\ axons\\,\\ and\\ the\\ formation\\ of\\ astrocytic\\ scars\\.\\ \\ lesions\\ have\\ a\\ predilection\\ for\\ the\\ optic\\ nerves\\,\\ periventreicular\\ white\\ matter\\,\\ brain\\ stem\\,\\ cerebellum\\,\\ and\\ spinal\\ cord\\ white\\ matter\\.\\ \\ lesions\\ are\\ usually\\ round\\ or\\ ovoid\\,\\ thought\\ they\\ may\\ also\\ have\\ finger\\-like\\ extensions\\ along\\ the\\ path\\ of\\ small\\ or\\ medium\\-sized\\ blood\\ vessels\\ \\(dawson\\â\\€\\™s\\ fingers\\)\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\	the\\ diagnosis\\ of\\ multiple\\ sclerosis\\ is\\ based\\ on\\ established\\ clinical\\,\\ laboratory\\ and\\ radiological\\ findings\\.\\ \\ patients\\ with\\ the\\ relapsing\\ forms\\ of\\ multiple\\ sclerosis\\ usually\\ present\\ with\\ sensory\\ disturbances\\,\\ unilateral\\ optic\\ neuritis\\,\\ diplopia\\,\\ limb\\ weakness\\,\\ gait\\ ataxia\\,\\ and\\ neurogenic\\ bladder\\ and\\ bowel\\.\\ \\ prominent\\ cortical\\ signs\\ and\\ extrapyamidal\\ phenomena\\ can\\ also\\ present\\ but\\ are\\ rarely\\ predominant\\ features\\ of\\ the\\ clinical\\ presentation\\.\\ \\ laboratory\\ workup\\ typically\\ includes\\ a\\ cerebrospinal\\ fluid\\ analysis\\,\\ which\\ often\\ shows\\ increased\\ intrathecal\\ synthesis\\ of\\ immunoglobulins\\ of\\ restricted\\ specificity\\ \\(oligoclonal\\ bands\\ of\\ igg\\)\\ with\\ moderate\\ lymphocytic\\ pleocytosis\\.\\ \\ cole\\ and\\ colleagues\\ have\\ suggested\\ that\\ the\\ presence\\ of\\ oligoclonal\\ bands\\ in\\ cerebrospinal\\ fluid\\ slightly\\ increases\\ the\\ risk\\ of\\ recurrent\\ disease\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\	mri\\ is\\ the\\ preferred\\ imaging\\ modality\\ to\\ study\\ suspected\\ ms\\ as\\ it\\ depicts\\ the\\ frequency\\,\\ shape\\,\\ and\\ location\\ of\\ the\\ characteristic\\ ms\\ lesions\\.\\ \\ these\\ lesions\\ have\\ discrete\\ foci\\ with\\ well\\-defined\\ margins\\ that\\ are\\ commonly\\ located\\ in\\ a\\ periventricular\\ location\\,\\ in\\ the\\ deep\\ white\\ matter\\,\\ adjacent\\ to\\ the\\ atria\\,\\ occipital\\ horns\\,\\ and\\ the\\ body\\ of\\ the\\ lateral\\ ventricles\\.\\ \\ t2\\-weighted\\ images\\ reflect\\ a\\ broad\\ spectrum\\ of\\ pathological\\ changes\\,\\ including\\ inflammation\\,\\ edema\\,\\ demyelination\\,\\ gliosis\\,\\ and\\ axonal\\ loss\\.\\ \\ many\\ of\\ the\\ hyperintense\\ t2\\-weighted\\ lesions\\ have\\ little\\ clinical\\ significance\\,\\ as\\ they\\ are\\ more\\ likely\\ to\\ be\\ chronic\\ ms\\ lesions\\.\\ \\ hence\\,\\ there\\ is\\ no\\ correlation\\ with\\ the\\ number\\ of\\ brain\\ lesions\\ detected\\ with\\ a\\ t2\\-weighted\\ sequence\\ and\\ the\\ patient\\â\\€\\™s\\ level\\ of\\ functional\\ disability\\.\\ \\ studies\\ have\\ shown\\ that\\ fluid\\-attenuated\\ inversion\\ recovery\\ \\(flair\\)\\ sequences\\ are\\ superior\\ to\\ t2\\-weighted\\ images\\ for\\ detecting\\ ms\\ brain\\ lesions\\ as\\ it\\ can\\ detect\\ many\\ cortical\\ and\\ juxtacortial\\ lesions\\ in\\ ms\\,\\ which\\ may\\ present\\ in\\ secondary\\ progressive\\ disease\\ and\\ often\\ missed\\ by\\ other\\ sequences\\.\\ \\ furthermore\\,\\ gadolinium\\-dtpa\\ injection\\,\\ a\\ paramagnetic\\ contrast\\ agent\\ that\\ crosses\\ only\\ disrupted\\ blood\\-brain\\-barrier\\,\\ may\\ demonstrate\\ foci\\ of\\ demyelination\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ms\\:\\ 0\\.3980505763511839\ \(0\)\
\-\ the\\:\\ 0\\.2453901257410052\ \(0\)\
\-\ lesions\\:\\ 0\\.23542980899301547\ \(0\)\
\-\ of\\:\\ 0\\.21598309030412427\ \(0\)\
\-\ oligoclonal\\:\\ 0\\.16402004612146592\ \(0\)\
\-\ and\\:\\ 0\\.13683578164555407\ \(0\)\
\-\ bands\\:\\ 0\\.13387496526567436\ \(0\)\
\-\ have\\:\\ 0\\.12602127568970292\ \(0\)\
\-\ in\\:\\ 0\\.1255117566530192\ \(0\)\
\-\ sclerosis\\:\\ 0\\.11230274670739739\ \(0\)\
\-\ igg\\:\\ 0\\.11152000218226027\ \(0\)\
\-\ are\\:\\ 0\\.10768939663030182\ \(0\)\
\-\ brain\\:\\ 0\\.09828916959816786\ \(0\)\
\-\ matter\\:\\ 0\\.09604016948319219\ \(0\)\
\-\ dawson\\:\\ 0\\.09072711630784913\ \(0\)\
\-\ callosum\\:\\ 0\\.0891051566316752\ \(0\)\
\-\ relapsing\\:\\ 0\\.08700711823422119\ \(0\)\
\-\ corpus\\:\\ 0\\.08624495638436114\ \(0\)\
\-\ white\\:\\ 0\\.08321935723993439\ \(0\)\
\-\ myelin\\:\\ 0\\.08306376136862302\ \(0\)\
\-\ that\\:\\ 0\\.08210586007201957\ \(0\)\
\-\ clinical\\:\\ 0\\.07993752847051125\ \(0\)\
\-\ igm\\:\\ 0\\.07934376329499508\ \(0\)\
\-\ cerebrospinal\\:\\ 0\\.07934376329499508\ \(0\)\
\-\ multiple\\:\\ 0\\.07711834405525987\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.0754004064293969\ \(0\)\
\-\ nervous\\:\\ 0\\.07338468041626409\ \(0\)\
\-\ demyelination\\:\\ 0\\.07338468041626409\ \(0\)\
\-\ ab\\:\\ 0\\.07293335717336619\ \(0\)\
\-\ predominance\\:\\ 0\\.06986389285234332\ \(0\)\
\-\ studies\\:\\ 0\\.06939427539068062\ \(0\)\
\-\ lyme\\:\\ 0\\.06921335909973825\ \(0\)\
\-\ prevalence\\:\\ 0\\.06890190514710057\ \(0\)\
\-\ laboratory\\:\\ 0\\.06869590583445878\ \(0\)\
\-\ with\\:\\ 0\\.06792095833257902\ \(0\)\
\-\ fingers\\:\\ 0\\.06746405282558132\ \(0\)\
\-\ stem\\:\\ 0\\.06668331318228073\ \(0\)\
\-\ pathological\\:\\ 0\\.06572132547703798\ \(0\)\
\-\ radiological\\:\\ 0\\.06549336102611032\ \(0\)\
\-\ periventricular\\:\\ 0\\.06483638257255482\ \(0\)\
\-\ present\\:\\ 0\\.06472323250136156\ \(0\)\
\-\ multifocal\\:\\ 0\\.061238550207874456\ \(0\)\
\-\ is\\:\\ 0\\.06044943738389904\ \(0\)\
\-\ usually\\:\\ 0\\.059554317682636713\ \(0\)\
\-\ sensory\\:\\ 0\\.05940343775445014\ \(0\)\
\-\ seen\\:\\ 0\\.05938266442455806\ \(0\)\
\-\ negative\\:\\ 0\\.05856632409775955\ \(0\)\
\-\ loss\\:\\ 0\\.05763389610099393\ \(0\)\
\-\ has\\:\\ 0\\.05761414047118512\ \(0\)\
\-\ serum\\:\\ 0\\.0565529089870239\ \(0\)\
\-\ to\\:\\ 0\\.05518300416792248\ \(0\)\
\-\ fluid\\:\\ 0\\.054620059405157705\ \(0\)\
\-\ optic\\:\\ 0\\.0542887256826802\ \(0\)\
\-\ patients\\:\\ 0\\.05321777437385429\ \(0\)\
\-\ disease\\:\\ 0\\.05294639260103632\ \(0\)\
\-\ foci\\:\\ 0\\.0515466804927623\ \(0\)\
\-\ inflammation\\:\\ 0\\.05068634450733397\ \(0\)\
\-\ sequences\\:\\ 0\\.05045234880636998\ \(0\)\
\-\ eighty\\:\\ 0\\.050428760251552976\ \(0\)\
\-\ pathogenetic\\:\\ 0\\.050428760251552976\ \(0\)\
\-\ demyelinated\\:\\ 0\\.050428760251552976\ \(0\)\
\-\ periventreicular\\:\\ 0\\.050428760251552976\ \(0\)\
\-\ extrapyamidal\\:\\ 0\\.050428760251552976\ \(0\)\
\-\ cole\\:\\ 0\\.050428760251552976\ \(0\)\
\-\ juxtacortial\\:\\ 0\\.050428760251552976\ \(0\)\
\-\ hyperintense\\:\\ 0\\.05016665114765809\ \(0\)\
\-\ many\\:\\ 0\\.04972435680209122\ \(0\)\
\-\ includes\\:\\ 0\\.049041353469122154\ \(0\)\
\-\ it\\:\\ 0\\.04842450942139864\ \(0\)\
\-\ progressive\\:\\ 0\\.04830237797097628\ \(0\)\
\-\ burgdorferi\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ periatrial\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ cadasil\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ chorea\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ northern\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ hypocellular\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ extensions\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ colleagues\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ paramagnetic\\:\\ 0\\.048187372616971216\ \(0\)\
\-\ system\\:\\ 0\\.04811338389584862\ \(0\)\
\-\ may\\:\\ 0\\.04760579301771982\ \(0\)\
\-\ cord\\:\\ 0\\.04674890146063443\ \(0\)\
\-\ ena\\:\\ 0\\.04659708278193992\ \(0\)\
\-\ disseminate\\:\\ 0\\.04659708278193992\ \(0\)\
\-\ shifts\\:\\ 0\\.04659708278193992\ \(0\)\
\-\ weakness\\:\\ 0\\.046027609807837086\ \(0\)\
\-\ cardiolipin\\:\\ 0\\.045363558153924566\ \(0\)\
\-\ ds\\:\\ 0\\.045363558153924566\ \(0\)\
\-\ multifactorial\\:\\ 0\\.045363558153924566\ \(0\)\
\-\ pleocytosis\\:\\ 0\\.045363558153924566\ \(0\)\
\-\ depicts\\:\\ 0\\.045363558153924566\ \(0\)\
\-\ cortical\\:\\ 0\\.04527777103878386\ \(0\)\
\-\ they\\:\\ 0\\.04506238986045251\ \(0\)\
\-\ spinal\\:\\ 0\\.0447815904070555\ \(0\)\
\-\ also\\:\\ 0\\.04449721303044181\ \(0\)\
\-\ arteriopathy\\:\\ 0\\.04435569514735816\ \(0\)\
\-\ minority\\:\\ 0\\.04435569514735816\ \(0\)\
\-\ astrocytic\\:\\ 0\\.04435569514735816\ \(0\)\
\-\ synthesis\\:\\ 0\\.04435569514735816\ \(0\)\
\-\ location\\:\\ 0\\.04391532524061464\ \(0\)\
\-\ images\\:\\ 0\\.043758880948834636\ \(0\)\
\-\ postulated\\:\\ 0\\.043503559117110596\ \(0\)\
\-\ axons\\:\\ 0\\.043503559117110596\ \(0\)\
\-\ which\\:\\ 0\\.04301564262301598\ \(0\)\
\-\ immunoglobulins\\:\\ 0\\.042765405312326865\ \(0\)\
\-\ central\\:\\ 0\\.042115330641317617\ \(0\)\
\-\ disabling\\:\\ 0\\.042114307512776394\ \(0\)\
\-\ europe\\:\\ 0\\.042114307512776394\ \(0\)\
\-\ body\\:\\ 0\\.04150610986101829\ \(0\)\
\-\ several\\:\\ 0\\.04137799852989604\ \(0\)\
\-\ often\\:\\ 0\\.04115107389878268\ \(0\)\
\-\ iga\\:\\ 0\\.04100501153036648\ \(0\)\
\-\ hallmark\\:\\ 0\\.04100501153036648\ \(0\)\
\-\ intrathecal\\:\\ 0\\.04100501153036648\ \(0\)\
\-\ axonal\\:\\ 0\\.04100501153036648\ \(0\)\
\-\ dna\\:\\ 0\\.04008154622550353\ \(0\)\
\-\ highest\\:\\ 0\\.04008154622550353\ \(0\)\
\-\ phenomena\\:\\ 0\\.04008154622550353\ \(0\)\
\-\ reflect\\:\\ 0\\.04008154622550353\ \(0\)\
\-\ atria\\:\\ 0\\.03967188164749754\ \(0\)\
\-\ heterogeneity\\:\\ 0\\.039290493049729744\ \(0\)\
\-\ perpendicular\\:\\ 0\\.03893372784271381\ \(0\)\
\-\ ue\\:\\ 0\\.03893372784271381\ \(0\)\
\-\ primary\\:\\ 0\\.03877926975648752\ \(0\)\
\-\ consisted\\:\\ 0\\.03828263004316333\ \(0\)\
\-\ gliosis\\:\\ 0\\.03828263004316333\ \(0\)\
\-\ crosses\\:\\ 0\\.03828263004316333\ \(0\)\
\-\ as\\:\\ 0\\.03800424930423806\ \(0\)\
\-\ chronic\\:\\ 0\\.03743464166429786\ \(0\)\
\-\ however\\:\\ 0\\.03732816362618732\ \(0\)\
\-\ subtype\\:\\ 0\\.037173334060753425\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.03692760729174362\ \(0\)\
\-\ scars\\:\\ 0\\.03692760729174362\ \(0\)\
\-\ disrupted\\:\\ 0\\.03692760729174362\ \(0\)\
\-\ been\\:\\ 0\\.036743423839408144\ \(0\)\
\-\ blood\\:\\ 0\\.03662678192980977\ \(0\)\
\-\ predilection\\:\\ 0\\.03646667858668309\ \(0\)\
\-\ detecting\\:\\ 0\\.03646667858668309\ \(0\)\
\-\ occurrence\\:\\ 0\\.036249868755890466\ \(0\)\
\-\ today\\:\\ 0\\.036249868755890466\ \(0\)\
\-\ disturbances\\:\\ 0\\.036249868755890466\ \(0\)\
\-\ hence\\:\\ 0\\.036249868755890466\ \(0\)\
\-\ specificity\\:\\ 0\\.03604124240858157\ \(0\)\
\-\ borderline\\:\\ 0\\.035646221394327306\ \(0\)\
\-\ predominately\\:\\ 0\\.035646221394327306\ \(0\)\
\-\ unclear\\:\\ 0\\.03545881558011668\ \(0\)\
\-\ predominant\\:\\ 0\\.03545881558011668\ \(0\)\
\-\ lymphocytic\\:\\ 0\\.03545881558011668\ \(0\)\
\-\ significance\\:\\ 0\\.03545881558011668\ \(0\)\
\-\ missed\\:\\ 0\\.03527755533861652\ \(0\)\
\-\ agent\\:\\ 0\\.03527755533861652\ \(0\)\
\-\ neuritis\\:\\ 0\\.035102050373100754\ \(0\)\
\-\ horns\\:\\ 0\\.035102050373100754\ \(0\)\
\-\ path\\:\\ 0\\.03493194642617166\ \(0\)\
\-\ disability\\:\\ 0\\.03476692097485349\ \(0\)\
\-\ inversion\\:\\ 0\\.03476692097485349\ \(0\)\
\-\ begins\\:\\ 0\\.034606679549869124\ \(0\)\
\-\ united\\:\\ 0\\.034450952573550284\ \(0\)\
\-\ preservation\\:\\ 0\\.034450952573550284\ \(0\)\
\-\ neurogenic\\:\\ 0\\.034299492631085685\ \(0\)\
\-\ furthermore\\:\\ 0\\.034299492631085685\ \(0\)\
\-\ disseminated\\:\\ 0\\.034152072105741775\ \(0\)\
\-\ subcortical\\:\\ 0\\.0340084811213087\ \(0\)\
\-\ established\\:\\ 0\\.0340084811213087\ \(0\)\
\-\ detect\\:\\ 0\\.0340084811213087\ \(0\)\
\-\ adem\\:\\ 0\\.03386852574508539\ \(0\)\
\-\ preferred\\:\\ 0\\.03346874131641859\ \(0\)\
\-\ decade\\:\\ 0\\.033217427945534915\ \(0\)\
\-\ potentially\\:\\ 0\\.03309592982213056\ \(0\)\
\-\ plaque\\:\\ 0\\.03309592982213056\ \(0\)\
\-\ increases\\:\\ 0\\.03309592982213056\ \(0\)\
\-\ can\\:\\ 0\\.03309545132453805\ \(0\)\
\-\ diplopia\\:\\ 0\\.032977044765228974\ \(0\)\
\-\ or\\:\\ 0\\.032909717790475336\ \(0\)\
\-\ forms\\:\\ 0\\.03286066273851899\ \(0\)\
\-\ estimated\\:\\ 0\\.03274668051305516\ \(0\)\
\-\ discrete\\:\\ 0\\.03263500111707003\ \(0\)\
\-\ autosomal\\:\\ 0\\.03252553334027172\ \(0\)\
\-\ largest\\:\\ 0\\.03210813196312501\ \(0\)\
\-\ spectrum\\:\\ 0\\.03200852670827143\ \(0\)\
\-\ spasm\\:\\ 0\\.031910684471160015\ \(0\)\
\-\ sequence\\:\\ 0\\.03181454392471424\ \(0\)\
\-\ rapidly\\:\\ 0\\.0315357650866334\ \(0\)\
\-\ limb\\:\\ 0\\.0315357650866334\ \(0\)\
\-\ ovoid\\:\\ 0\\.031445877869003463\ \(0\)\
\-\ correlation\\:\\ 0\\.031445877869003463\ \(0\)\
\-\ percent\\:\\ 0\\.031184666658262052\ \(0\)\
\-\ modality\\:\\ 0\\.031184666658262052\ \(0\)\
\-\ genetic\\:\\ 0\\.0311002689565586\ \(0\)\
\-\ little\\:\\ 0\\.031017140441425686\ \(0\)\
\-\ recovery\\:\\ 0\\.031017140441425686\ \(0\)\
\-\ functional\\:\\ 0\\.03093524350524043\ \(0\)\
\-\ ataxia\\:\\ 0\\.030619275103937228\ \(0\)\
\-\ detected\\:\\ 0\\.03024813292631104\ \(0\)\
\-\ remains\\:\\ 0\\.030036848275472337\ \(0\)\
\-\ frequency\\:\\ 0\\.02996817730438675\ \(0\)\
\-\ shape\\:\\ 0\\.029900348943177606\ \(0\)\
\-\ mechanism\\:\\ 0\\.02970171887722507\ \(0\)\
\-\ workup\\:\\ 0\\.02970171887722507\ \(0\)\
\-\ dominant\\:\\ 0\\.029509979121527308\ \(0\)\
\-\ suggested\\:\\ 0\\.029509979121527308\ \(0\)\
\-\ nerves\\:\\ 0\\.029447515834512033\ \(0\)\
\-\ rapid\\:\\ 0\\.029324667621448086\ \(0\)\
\-\ analysis\\:\\ 0\\.029324667621448086\ \(0\)\
\-\ vasculitis\\:\\ 0\\.029264252352517502\ \(0\)\
\-\ number\\:\\ 0\\.029028985268905936\ \(0\)\
\-\ characterized\\:\\ 0\\.02897170038234775\ \(0\)\
\-\ cerebellum\\:\\ 0\\.02897170038234775\ \(0\)\
\-\ unilateral\\:\\ 0\\.028858881321976834\ \(0\)\
\-\ broad\\:\\ 0\\.028481216498067393\ \(0\)\
\-\ oriented\\:\\ 0\\.028429310557232534\ \(0\)\
\-\ rarely\\:\\ 0\\.028127711652150812\ \(0\)\
\-\ relative\\:\\ 0\\.027935416017113884\ \(0\)\
\-\ states\\:\\ 0\\.027704087617020347\ \(0\)\
\-\ ventricles\\:\\ 0\\.027704087617020347\ \(0\)\
\-\ injection\\:\\ 0\\.027438695433874647\ \(0\)\
\-\ gait\\:\\ 0\\.027310629271916752\ \(0\)\
\-\ wrist\\:\\ 0\\.027226870971299395\ \(0\)\
\-\ thought\\:\\ 0\\.027226870971299395\ \(0\)\
\-\ incidence\\:\\ 0\\.0271443628413401\ \(0\)\
\-\ restricted\\:\\ 0\\.027103566035627375\ \(0\)\
\-\ occipital\\:\\ 0\\.02698295160530837\ \(0\)\
\-\ margins\\:\\ 0\\.026903979661034156\ \(0\)\
\-\ flair\\:\\ 0\\.026826120034703967\ \(0\)\
\-\ by\\:\\ 0\\.026781815047558215\ \(0\)\
\-\ disorder\\:\\ 0\\.026673615408860336\ \(0\)\
\-\ infarct\\:\\ 0\\.026239828863485627\ \(0\)\
\-\ 28\\:\\ 0\\.02617072868768817\ \(0\)\
\-\ life\\:\\ 0\\.025870041407612013\ \(0\)\
\-\ total\\:\\ 0\\.025837619366965194\ \(0\)\
\-\ round\\:\\ 0\\.025837619366965194\ \(0\)\
\-\ suspected\\:\\ 0\\.025837619366965194\ \(0\)\
\-\ characteristic\\:\\ 0\\.025492990151835027\ \(0\)\
\-\ best\\:\\ 0\\.025372812764808638\ \(0\)\
\-\ features\\:\\ 0\\.025372812764808638\ \(0\)\
\-\ recurrent\\:\\ 0\\.025284363804526134\ \(0\)\
\-\ arm\\:\\ 0\\.025168591152460833\ \(0\)\
\-\ there\\:\\ 0\\.025094078425930023\ \(0\)\
\-\ formation\\:\\ 0\\.024999355218736582\ \(0\)\
\-\ located\\:\\ 0\\.02494407533723086\ \(0\)\
\-\ csf\\:\\ 0\\.024916641325173988\ \(0\)\
\-\ prominent\\:\\ 0\\.02483514684554919\ \(0\)\
\-\ hand\\:\\ 0\\.02464953902845434\ \(0\)\
\-\ slightly\\:\\ 0\\.024597633087619482\ \(0\)\
\-\ deep\\:\\ 0\\.024546209999742403\ \(0\)\
\-\ vessels\\:\\ 0\\.02446996131385308\ \(0\)\
\-\ bladder\\:\\ 0\\.02446996131385308\ \(0\)\
\-\ shown\\:\\ 0\\.02444477702389889\ \(0\)\
\-\ complex\\:\\ 0\\.024296034182537753\ \(0\)\
\-\ sagittal\\:\\ 0\\.024247329531933905\ \(0\)\
\-\ worsening\\:\\ 0\\.0240801651979875\ \(0\)\
\-\ similar\\:\\ 0\\.024033317950800475\ \(0\)\
\-\ third\\:\\ 0\\.024010042370798047\ \(0\)\
\-\ moderate\\:\\ 0\\.023672181100944056\ \(0\)\
\-\ second\\:\\ 0\\.023607017964261588\ \(0\)\
\-\ commonly\\:\\ 0\\.023333197239728053\ \(0\)\
\-\ throughout\\:\\ 0\\.02319118724832268\ \(0\)\
\-\ based\\:\\ 0\\.022841937939247277\ \(0\)\
\-\ reported\\:\\ 0\\.02271186271236315\ \(0\)\
\-\ presence\\:\\ 0\\.022657039696902612\ \(0\)\
\-\ including\\:\\ 0\\.022566859196407454\ \(0\)\
\-\ risk\\:\\ 0\\.022531194930226255\ \(0\)\
\-\ intensity\\:\\ 0\\.02239079520352775\ \(0\)\
\-\ 25\\:\\ 0\\.02233905121807512\ \(0\)\
\-\ typically\\:\\ 0\\.02213678687179494\ \(0\)\
\-\ signs\\:\\ 0\\.022038363937998958\ \(0\)\
\-\ cerebral\\:\\ 0\\.021846624182301197\ \(0\)\
\-\ presentation\\:\\ 0\\.02170706142954364\ \(0\)\
\-\ given\\:\\ 0\\.021691769740446117\ \(0\)\
\-\ left\\:\\ 0\\.02151345619354115\ \(0\)\
\-\ areas\\:\\ 0\\.02140898696043653\ \(0\)\
\-\ available\\:\\ 0\\.021394496933571934\ \(0\)\
\-\ recent\\:\\ 0\\.021351253359069566\ \(0\)\
\-\ along\\:\\ 0\\.021126166099103148\ \(0\)\
\-\ study\\:\\ 0\\.021030500931432553\ \(0\)\
\-\ positive\\:\\ 0\\.020778886482577964\ \(0\)\
\-\ patient\\:\\ 0\\.020512459463497397\ \(0\)\
\-\ no\\:\\ 0\\.020508601189451123\ \(0\)\
\-\ superior\\:\\ 0\\.02050116889391651\ \(0\)\
\-\ adjacent\\:\\ 0\\.020439950747966236\ \(0\)\
\-\ area\\:\\ 0\\.020427788054206614\ \(0\)\
\-\ bowel\\:\\ 0\\.02023673864407125\ \(0\)\
\-\ approximately\\:\\ 0\\.02012060113542317\ \(0\)\
\-\ her\\:\\ 0\\.01970027514218633\ \(0\)\
\-\ only\\:\\ 0\\.01970027514218633\ \(0\)\
\-\ for\\:\\ 0\\.01911505882106719\ \(0\)\
\-\ changes\\:\\ 0\\.019057467776880894\ \(0\)\
\-\ level\\:\\ 0\\.019047994009208733\ \(0\)\
\-\ on\\:\\ 0\\.01904725189789659\ \(0\)\
\-\ abnormal\\:\\ 0\\.01894484027316963\ \(0\)\
\-\ focal\\:\\ 0\\.018861850426327653\ \(0\)\
\-\ likely\\:\\ 0\\.018843576220979166\ \(0\)\
\-\ edema\\:\\ 0\\.018807208049778874\ \(0\)\
\-\ secondary\\:\\ 0\\.018690637230456594\ \(0\)\
\-\ shows\\:\\ 0\\.018507373748462064\ \(0\)\
\-\ common\\:\\ 0\\.017883045696546838\ \(0\)\
\-\ signal\\:\\ 0\\.01787538395993058\ \(0\)\
\-\ these\\:\\ 0\\.017806902039719096\ \(0\)\
\-\ more\\:\\ 0\\.01731520548852948\ \(0\)\
\-\ physical\\:\\ 0\\.017098129565071105\ \(0\)\
\-\ acute\\:\\ 0\\.01705836002603205\ \(0\)\
\-\ increased\\:\\ 0\\.01705175949738672\ \(0\)\
\-\ imaging\\:\\ 0\\.01657186518571053\ \(0\)\
\-\ woman\\:\\ 0\\.016422694178511894\ \(0\)\
\-\ most\\:\\ 0\\.016410932595173417\ \(0\)\
\-\ demonstrate\\:\\ 0\\.016393337008698196\ \(0\)\
\-\ other\\:\\ 0\\.016375797251782093\ \(0\)\
\-\ diagnosis\\:\\ 0\\.016346687431571933\ \(0\)\
\-\ small\\:\\ 0\\.016265986113880297\ \(0\)\
\-\ mri\\:\\ 0\\.01618644600658757\ \(0\)\
\-\ exam\\:\\ 0\\.01587392580993391\ \(0\)\
\-\ lateral\\:\\ 0\\.01564933043250093\ \(0\)\
\-\ but\\:\\ 0\\.015593312115333944\ \(0\)\
\-\ findings\\:\\ 0\\.015562994258258172\ \(0\)\
\-\ contrast\\:\\ 0\\.015321431829377116\ \(0\)\
\-\ female\\:\\ 0\\.015216316539595676\ \(0\)\
\-\ be\\:\\ 0\\.012791836904922825\ \(0\)\
\-\ not\\:\\ 0\\.012448633456853602\ \(0\)\
\-\ an\\:\\ 0\\.012058263635203306\ \(0\)\
\-\ this\\:\\ 0\\.010835441705756184\ \(0\)\
